UNIVERSITY OF NORTH CAROLINA HOSPITALS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1989-01-01

Employees: -

Market Cap: -

Website: http://www.unc.edu/interactive-tour/unc-hospitals/

Clinical Trials

ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Device: Ultrasound

First Posted Date: 2018-12-24

Last Posted Date: 2024-12-09

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT03785782

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Device: Intrinsic Subtyping of Primary Breast Cancer

First Posted Date: 2018-12-07

Last Posted Date: 2024-11-21

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 500

Registration Number: NCT03769415

Locations: 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
UNC Rex Healthcare, Raleigh, North Carolina, United States

Get REAL and HEEL Research Program

Completed

Conditions: Breast Cancer

Interventions: Behavioral: 16-week Exercise Rehabilitation Program for Breast Cancer Survivors

First Posted Date: 2018-11-30

Last Posted Date: 2021-09-02

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 35

Registration Number: NCT03760536

Locations: 🇺🇸
North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Phase 1

Recruiting

Conditions: Osteosarcoma
Neuroblastoma

Interventions: Biological: iC9.GD2.CAR.IL-15 T-cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2018-10-26

Last Posted Date: 2024-10-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT03721068

Locations: 🇺🇸
Emory - Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Registry for Adults With Plasma Cell Disorders (PCD's)

Recruiting

Conditions: Multiple Myeloma
Amyloidosis
Cryoglobulinemia
Light Chain Deposition Disease
Smoldering Multiple Myeloma
Heavy Chain Deposition Disease
Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes
Plasma Cell Leukemia
Castleman's Disease

First Posted Date: 2018-10-24

Last Posted Date: 2024-11-19

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 2000

Registration Number: NCT03717844

Locations: 🇺🇸
North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Phase 2

Completed

Conditions: Melanoma Stage Iii
Melanoma Stage Iv
Cutaneous Melanoma
Melanoma
Melanoma (Skin)

Interventions: Drug: Denosumab
Drug: Pembrolizumab
Drug: Nivolumab

First Posted Date: 2018-08-08

Last Posted Date: 2024-08-12

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT03620019

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Manchester, New Hampshire, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Phase 1

Recruiting

Conditions: Neoplasms
Cutaneous Lymphoma
Lymphoproliferative Disorders
Lymphomatoid Papulosis
Cutaneous T Cell Lymphoma
Immunoproliferative Disorders
Cutaneous Anaplastic Large Cell Lymphoma
Lymphatic Diseases
Mycosis Fungoides
Sezary Syndrome

Interventions: Biological: ATLCAR.CD30.CCR4 cells
Biological: ALTCAR.CD30 cells
Drug: Bendamustine
Drug: Fludarabine

First Posted Date: 2018-07-26

Last Posted Date: 2024-10-26

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 59

Registration Number: NCT03602157

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Trial of Parotid Sparing Whole Brain Radiation

Not Applicable

Completed

Conditions: Xerostomia

Interventions: Radiation: Standard WBRT
Radiation: Parotid sparing WBRT

First Posted Date: 2018-07-23

Last Posted Date: 2023-04-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 60

Registration Number: NCT03595878

Locations: 🇺🇸
Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill, North Carolina, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

Conditions: Acute Lymphoblastic Leukemia
Immune System Diseases
Immunoproliferative Disorders

First Posted Date: 2018-07-20

Last Posted Date: 2021-12-03

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Registration Number: NCT03594162

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

18-FLT PET/MR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant Patients

Early Phase 1

Terminated

Conditions: Graft Vs Host Disease

Interventions: Drug: Fluorothymidine (FLT)

First Posted Date: 2018-06-06

Last Posted Date: 2024-12-10

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 10

Registration Number: NCT03546556

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy